Provided are methods of treating eye diseases associated with inflammation and/or vascular proliferation using compounds of formula 1 or formula 8, wherein the variables are as defined in the specification. The compounds are analogues of tranilast. Preferred compounds include (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid and (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid.